SR&ED in biomedical and life sciences
Preclinical work, formulation development, medical device validation, bioprocess scale-up: most of the scientific work inside a life sciences company qualifies for the SR&ED tax credit. The difficulty is claiming it in the form the CRA expects.
- Formulation and bioprocess development
- Medical device validation and testing
- Work contracted out to a research centre
SR&ED applied to life sciences
SR&ED — scientific research and experimental development — is Canada's federal R&D tax credit programme. A Canadian-controlled private corporation recovers up to 35 % of its qualifying expenditures as a refundable cash payment, on a base of up to $6M per year; in Québec, the CRIC credit adds 30 % on the first $1M. For a life sciences company the base is dominated by scientific salaries and laboratory subcontracting — two lines that are both claimable, but not at the same rate.
- 01
A failed experiment counts as much as a successful one
An unstable formulation, an out-of-specification batch, an assay that disproves the hypothesis: scientific uncertainty is the very condition of eligibility. Many companies claim only the programmes that worked and leave behind the work that eliminated a dead end.
- 02
Contracted-out work
CROs, analytical labs, animal facilities, university centres: contracted R&D qualifies, at a fraction of the expenditure rather than in full. It is the single most frequently omitted line for companies without an in-house lab.
- 03
The line with regulatory production
A validation batch, an equipment qualification, a stability study: some of this is SR&ED, some is pure regulatory compliance. The distinction turns on whether a technological uncertainty existed, and it is documented while the work happens — not twelve months later.
Examples of eligible projects
Work that commonly qualifies among our clients in this sector. This list illustrates; it does not enumerate. A project absent from it is not a project excluded.
Commonly qualifying in this domain
- Developing a formulation or a delivery vehicle
- Developing and scaling up a bioprocess
- Technical design and validation of a medical device
- Analytical method or biomarker development
- Preclinical work and exploratory efficacy studies
- Custom laboratory automation or instrumentation
The sector trap: confusing the regulatory file with the tax file. A clinical study report is not SR&ED evidence — it describes an executed protocol, not the technological uncertainty you were trying to resolve. The two records are built in parallel.
Frequently asked questions
Partly. The phases where technological uncertainty remains — protocol development, analytical method development, exploratory studies — generally qualify. A study run solely to satisfy a regulatory requirement, under a fully established protocol, does not. The dividing line is the same as everywhere in SR&ED: were you resolving an uncertainty, or documenting an expected result?
Yes, and it is the most common case in life sciences. For a Canadian-controlled private corporation the enhanced federal credit is refundable: it is paid in cash even when the company owes no tax. That is what makes it an annual source of working capital for an early-stage biotech rather than a mere tax deduction.
Yes. R&D contracted to a Canadian third party is a qualifying expenditure, claimed at a fraction of its amount rather than in full, and the contract must show that the work is genuine R&D rather than a routine service. Work placed with a university or an approved research centre follows separate rules, often more favourable.
Yes. Government assistance — a federal or provincial grant, an agency contribution — reduces qualifying expenditures before the credit is computed. That does not make the grant a bad deal: stacking is almost always still worth it. But the order of the calculation changes the final number, and a claim that ignores it is routinely reviewed.
Hubvention is a Canadian firm specialised in public funding: SR&ED, CRIC, NRC IRAP and sector grants. We build the technical narrative with your scientists rather than from their final reports, which is the only way the technological uncertainty ends up described in the words the CRA looks for.